Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nonfusion Alternative To Artificial Discs Acquired By Abbott/Spinal Concepts

This article was originally published in The Gray Sheet

Executive Summary

Abbott Labs will launch a clinical trial early next year supporting a PMA submission for Spine Next's Wallis nonfusion spine stabilization device, having acquired the French manufacturer for $60 mil. and potential milestone payments

You may also be interested in...



Zimmer Rounds Out Spinal Offerings With Abbott Spine Acquisition

Zimmer's $360 million acquisition of Abbott's spinal surgery business will add pedicle screws and an interspinous stabilizer system to help round out Zimmer's own spinal offerings and create "critical mass" in the spinal business, the company says

Zimmer Rounds Out Spinal Offerings With Abbott Spine Acquisition

Zimmer's $360 million acquisition of Abbott's spinal surgery business will add pedicle screws and an interspinous stabilizer system to help round out Zimmer's own spinal offerings and create "critical mass" in the spinal business, the company says

Abbott’s Wallis trial

First subject implanted in the U.S. with the firm's Wallis dynamic stabilization spinal implant to treat degenerative disc disease as part of a 340-patient, 20-center clinical trial to support PMA approval. Unlike total disc replacement, such as Johnson & Johnson's Charité, the device does not require an abdominal insertion and does not replace the disc but instead re-routes spinal load through the use of spacers. Abbott acquired Wallis developer Spine Next for $60 mil. in 2004 (1"The Gray Sheet" Nov. 1, 2004, p. 5)...

Related Content

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel